Valuation: Spyre Therapeutics, Inc.

Market Cap 8.59B 7.52B 6.93B 6.4B 12.15B 820B 12.36B 82.85B 32.54B 404B 32.27B 31.57B 1,388B P/E 2026 *
-31.8x
P/E 2027 * -28.9x
Enterprise Value 8.02B 7.01B 6.47B 5.97B 11.33B 764B 11.52B 77.27B 30.34B 377B 30.09B 29.44B 1,295B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.17%
Yield 2026 *
-
Yield 2027 * -
1 day-1.02%
1 week+12.82%
Current month+10.09%
1 month+21.01%
3 months+90.56%
6 months+219.31%
Current year+198.35%
1 week 86.6
Extreme 86.6001
99.34
1 month 80.79
Extreme 80.7901
102.06
Current year 28
Extreme 28
102.06
1 year 14.5
Extreme 14.505
102.06
3 years 8.43
Extreme 8.43
102.06
5 years 2.66
Extreme 2.66
212.5
10 years 2.66
Extreme 2.66
300
Manager TitleAgeSince
Chief Executive Officer 36 2023-11-26
Director of Finance/CFO 49 2023-08-31
Chief Tech/Sci/R&D Officer - 2023-11-26
Director TitleAgeSince
Director/Board Member 39 2023-06-21
Chairman 54 -
Director/Board Member 62 2024-05-14
Date Insider Type Main position Quantity % Market Cap.
06-30Fiscal year

Chief Financial Officer

22,500 0.0259%
06-30Sell

Chief Executive Officer

-15,000 0.0173%
06-30Fiscal year

Chief Technology Officer

25,002 0.0288%
Change 5-day change 1-year change 3-year change Capi.($)
-1.02%+12.82%+522.94%+681.92% 8.59B
+1.84%-0.66%+59.82%+92.96% 54.88B
-4.14%-8.06%+58.96%+118.67% 54.63B
-2.24%+3.59%+17.75%+477.47% 25.06B
-1.60%-6.21%-18.96%-15.21% 23.14B
+2.43%+1.06%+42.44%-1.27% 19.87B
-3.19%0.00%+35.60%-26.98% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
+8.74%+3.51%+51.91%+726.40% 15.75B
-1.05%+1.16%+25.95%+194.27% 14.2B
Average -0.71%+1.03%+99.15%+260.54% 25.02B
Weighted average by Cap. -0.90%-0.96%+67.47%+194.48%

Financials

2026 *2027 *
Net sales - -
Net income -273M -238M -220M -203M -385M -26B -392M -2.63B -1.03B -12.81B -1.02B -1B -44.03B -311M -272M -251M -232M -440M -29.69B -448M -3B -1.18B -14.63B -1.17B -1.14B -50.29B
Net Debt -580M -507M -468M -432M -820M -55.29B -833M -5.59B -2.19B -27.24B -2.18B -2.13B -93.64B -485M -424M -391M -361M -686M -46.25B -697M -4.67B -1.84B -22.78B -1.82B -1.78B -78.32B
Logo Spyre Therapeutics, Inc.
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, specializing in long-acting antibodies and antibody combinations for inflammatory bowel disease (IBD) and rheumatic diseases. The Company's pipeline includes investigational extended half-life antibodies targeting a4b7, TL1A, and IL-23. It is advancing a pipeline of monoclonal antibodies (mAbs) for the treatment of IBD and other immune-mediated diseases. The Company's pipeline includes its SKYLINE Phase II platform trial evaluating SPY001, SPY002, SPY003, and pairwise combinations thereof in subjects with moderately to severely active UC and its SKYWAY basket trial evaluating SPY072 in three rheumatic diseases: rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA). SPY001 is a highly potent, highly selective, and humanized monoclonal immunoglobulin G1 investigational antibody designed to bind selectively to the a4b7 integrin being developed for the treatment of IBD (UC and CD).
Employees
112
Date Price Change Volume
26-07-10 US$97.74 -1.02% 779,183
26-07-09 US$98.75 +3.51% 1,329,833
26-07-08 US$95.40 +1.24% 1,240,474
26-07-07 US$94.23 +6.19% 1,305,918
26-07-06 US$88.74 +2.44% 1,388,917
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
97.74USD
Average target price
101.53USD
Spread / Average Target
+3.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. SYRE Stock